Clinical trial
A Phase I Study of Intra-anally Administered Lopinavir/Ritonavir in People Living With HIV (PLWH) With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
NCT05334004 is registered in ClinicalTrials.gov with University of Wisconsin, Madison as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study of Intra-anally Administered Lopinavir/Ritonavir in People Living With HIV (PLWH) With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)
- Lead sponsor
- University of Wisconsin, Madison
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- December 19, 2023
- Completion date
- June 30, 2027
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
high-grade anal intraepithelial neoplasia